Pancreatic ductal adenocarcinoma(PDAC)is a devastating malignancy,owing in part to the fact that most patients present with advanced disease with only 20%eligible for surgical resection.Moreover,the dismal oncologic o...Pancreatic ductal adenocarcinoma(PDAC)is a devastating malignancy,owing in part to the fact that most patients present with advanced disease with only 20%eligible for surgical resection.Moreover,the dismal oncologic outcomes achieved with surgery alone,coupled with the almost ubiquitous distant recurrence in operable PDAC patients,have mandated a multimodal approach for this disease.The advent of effective combination chemotherapy regimens delivered increasingly in the perioperative setting,safety and technical mastery of pancreatectomy,and growing appreciation of the molecular underpinnings in PDAC have resulted in gradual but consistent improvements in disease-specific survival and overall survival(OS)in patients with localized PDAC(1).展开更多
文摘Pancreatic ductal adenocarcinoma(PDAC)is a devastating malignancy,owing in part to the fact that most patients present with advanced disease with only 20%eligible for surgical resection.Moreover,the dismal oncologic outcomes achieved with surgery alone,coupled with the almost ubiquitous distant recurrence in operable PDAC patients,have mandated a multimodal approach for this disease.The advent of effective combination chemotherapy regimens delivered increasingly in the perioperative setting,safety and technical mastery of pancreatectomy,and growing appreciation of the molecular underpinnings in PDAC have resulted in gradual but consistent improvements in disease-specific survival and overall survival(OS)in patients with localized PDAC(1).
